Vaginitis test company raises $25M

Nanopath has raised a $25 million Series B round of funding to further research on its clinical diagnostic platform that has created a 15-minute test for vaginitis. The funding will also help support the commercial launch of the test, including manufacturing and clinical support. Nanopath has received FDA Breakthrough Device designation already for a test for complicated urinary tract infections. One in three women will experience vaginitis in their lifetime and traditional tests can take days or weeks to deliver accurate results.